Skip to main content
SpringerLink
Log in

Thérapeutiques du cancer de l’ovaire

  • Chapter
Book cover Thérapeutique du cancer

  • 771 Accesses

Résumé

Le but du traitement chirurgical du cancer épithélial de l’ovaire est de réaliser une stadification anatomique précise et une réduction tumorale optimale.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47: 159–166

    Article  PubMed  CAS  Google Scholar 

  2. Lhomme C, Morice P, Planchamp F et al. (2008) [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer—update. According to the methodology of Standards, Options: Recommendations (SOR)]. Bull Cancer 95: 881–886

    PubMed  Google Scholar 

  3. Angioli R, Plotti F, Palaia I et al. (2008) Update on lymphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gynecol 20: 34–39

    Article  PubMed  Google Scholar 

  4. Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90: 390–396

    Article  PubMed  Google Scholar 

  5. Trimbos JB, Bolis G (1994) Guidelines for surgical staging of ovarian cancer. Obstet Gynecol Surv 49: 814–816

    Article  PubMed  CAS  Google Scholar 

  6. Lhomme C, Planchamp F, Joly F et al. (2007) [Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment]. Bull Cancer 94: 1093–1106

    PubMed  CAS  Google Scholar 

  7. Morice P, Brehier-Ollive D, Rey A et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14: 74–77

    Article  PubMed  CAS  Google Scholar 

  8. Neijt JP, Bokkel Huinink WW, van der Burg ME et al. (1991) Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27: 1367–1372

    Article  PubMed  CAS  Google Scholar 

  9. du Bois A, Reuss A, Pujade-Lauraine E et al. (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115: 1234–1244

    Article  PubMed  CAS  Google Scholar 

  10. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259

    Article  PubMed  Google Scholar 

  11. Hacker NF, Berek JS, Lagasse LD et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–420

    PubMed  CAS  Google Scholar 

  12. Eisenkop SM, Spirtos NM (2004) The relative importance of surgical training and laboratory research in a gynecologic oncology fellowship. Int J Gynecol Cancer 14: 23–34

    Article  PubMed  CAS  Google Scholar 

  13. Hermanek PSLH (1992) UICC TNM Classification of malignant tumours, 4 ed., Springer-Verlag, Berlin

    Google Scholar 

  14. van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–634

    Article  PubMed  Google Scholar 

  15. Tangjitgamol S et al. (2009) Interval debulking surgery for advanced epithelial ovarian cancer: a cochrane systematic review. Gynecol Oncol 112: 257–264

    Article  PubMed  Google Scholar 

  16. Vergote I, Trope C, Amant F et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med 363: 943–953

    Article  PubMed  CAS  Google Scholar 

  17. (1995) Evidence-based medicine, in its place [editorial] [see comments]. Lancet 346: 785

    Google Scholar 

  18. Neijt JP, Aartsen EJ, Bouma J et al. (1985) Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer. Prog Clin Biol Res 201: 217–223

    PubMed  CAS  Google Scholar 

  19. Stuart G, Avall-Lundqvist E, du Bois A et al. (2005) 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 16Suppl 8: viii36–viii38

    Article  PubMed  Google Scholar 

  20. Chi DS, Liao JB, Leon LF et al. (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: 532–537

    Article  PubMed  CAS  Google Scholar 

  21. Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69: 103–108

    Article  PubMed  CAS  Google Scholar 

  22. du Bois A, Harter P (2006) The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 17(Suppl 10): x235–x240

    Article  PubMed  Google Scholar 

  23. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recuurent ovarian cancer: a meta analysis. Gynecol Oncol 112: 1

    Article  PubMed  Google Scholar 

  24. du Bois A, Schmalfeldt B, Meier W et al. (2006) [Ovarian cancer — can peritoneal therapy be regarded as new standard?]. Zentralbl Gynakol 128: 202–206

    Article  PubMed  Google Scholar 

  25. Harter P, du Bois A (2005) The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol 17: 505–514

    Article  PubMed  Google Scholar 

  26. Hoskins WJ, McGuire WP, Brady MF et al. (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974–979

    Article  PubMed  CAS  Google Scholar 

  27. Ozols RF, Bundy BN, Greer BE et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194–3200

    Article  PubMed  CAS  Google Scholar 

  28. Piccart MJ, Bertelsen K, James K et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708

    Article  PubMed  CAS  Google Scholar 

  29. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  30. Muggia FM, Braly PS, Brady MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18: 106–115

    PubMed  CAS  Google Scholar 

  31. Lhomme C, Ray-Coquard I, Guastalla JP et al. (2004) [Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]. Bull Cancer 91: 609–620

    PubMed  Google Scholar 

  32. Anderson CM, Chambers S, Clamp M et al. (1988) Can audit improve patient care? Effects of studying use of digoxin in general practice. BMJ 297: 113–114

    Article  PubMed  CAS  Google Scholar 

  33. NIH consensus conference (1991) Treatment of early-stage breast cancer. JAMA 265: 391–395

    Article  Google Scholar 

  34. du Bois A, Luck HJ, Bauknecht T et al. (1999) First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 17: 46–51

    PubMed  Google Scholar 

  35. Neijt JP, du Bois A (1999) Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Semin Oncol 26(1 Suppl 2): 78–83

    PubMed  CAS  Google Scholar 

  36. Calvert AH, Newell DR, Gumbrell LA et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756

    PubMed  CAS  Google Scholar 

  37. (1998) ICON2: randomised trial of single-agent carboplatin against threedrug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 352: 1571–1576

    Google Scholar 

  38. Harper P (1997) ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Semin Oncol 24(5 Suppl 15): S15

    PubMed  CAS  Google Scholar 

  39. Bookman MA, Brady MF, McGuire WP et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419–1425

    Article  PubMed  CAS  Google Scholar 

  40. Katsumata N, Yasuda M, Takahashi F et al. (2009) Japanese Gynecologic Oncologic Oncology Group. Dose dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase III, open label, randomised controlled trial. Lancet 374: 1331–1338

    Article  PubMed  CAS  Google Scholar 

  41. Levin L, Lund B, Heintz AP (1993) Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 4Suppl 4: 23–29

    Article  PubMed  Google Scholar 

  42. Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756–767

    PubMed  CAS  Google Scholar 

  43. Murphy WK, Fossella FV, Winn RJ et al. (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384–388

    Article  PubMed  CAS  Google Scholar 

  44. McGuire WP, Hoskins WJ, Brady MF et al. (1995) Assessment of doseintensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589–1599

    PubMed  CAS  Google Scholar 

  45. Kaye SB, Paul J, Cassidy J et al. (1996) Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 14: 2113–2119

    PubMed  CAS  Google Scholar 

  46. Kerbrat P, Lhomme C, Fervers B et al. (2001) [Standards, options and recommendations for the initial management of patients with malignant ovarian epithelial tumors (abridged version)]. Gynecol Obstet Fertil 29: 733–742

    Article  PubMed  CAS  Google Scholar 

  47. Piccart MJ, Gore M, ten Bokkel HW et al. (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87: 676–681

    Article  PubMed  CAS  Google Scholar 

  48. Vasey PA (2001) Preliminary results of the SCOTROC trial: A phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first line chemotherapy for stage IC-IV epithelial ovarian cancer. J Clin Oncol 20[804], 202a. Ref Type: Abstract

    Google Scholar 

  49. Vasey PA (2002) Survival and long term toxicity results of the SCOTROC trial: doceptaxel-carboplatin vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer. J Clin Oncol [804], 202a. Ref Type: Abstract

    Google Scholar 

  50. (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 9: 1668–1674

    Google Scholar 

  51. Fanning J, Bennett TZ, Hilgers RD (1992) Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80: 954–960

    PubMed  CAS  Google Scholar 

  52. A’Hern RP, Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13: 726–732

    PubMed  Google Scholar 

  53. du Bois A, Weber B, Rochon J et al. (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 24: 1127–1135

    Article  PubMed  CAS  Google Scholar 

  54. Kristensen GB, Vergote I, Stuart G et al. (2003) First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13Suppl 2: 172–177

    Article  PubMed  Google Scholar 

  55. Savarese A, Sorio R, Breda E et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: Final analysis of the MITO-2 randomized multicenter trial. Pro Am Soc Clin Oncol 28: abstr 5033

    Google Scholar 

  56. Gershenson DM, Mitchell MF, Atkinson N et al. (1992) The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “maintenance” therapy reconsidered. Gynecol Oncol 47: 7–13

    Article  PubMed  CAS  Google Scholar 

  57. Hakes TB, Chalas E, Hoskins WJ et al. (1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45: 284–289

    Article  PubMed  CAS  Google Scholar 

  58. Bertelsen K, Jakobsen A, Stroyer J et al. (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49: 30–36

    Article  PubMed  CAS  Google Scholar 

  59. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE (1997) A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 8: 327–333

    Article  PubMed  CAS  Google Scholar 

  60. Markman M, Liu PY, Wilczynski S et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460–2465

    Article  PubMed  CAS  Google Scholar 

  61. De Placido S, Scambia G, Di Vagno G et al. (2004) Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22: 2635–2642

    Article  PubMed  CAS  Google Scholar 

  62. Pfisterer J, Weber B, Reuss A et al. (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGOOVAR and GINECO. J Natl Cancer Inst 98: 1036–1045

    Article  PubMed  CAS  Google Scholar 

  63. Vasey PA, Atkinson R, Osborne R et al. (2006) SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94: 62–68

    Article  PubMed  CAS  Google Scholar 

  64. Gordon AN, Teneriello MG, Spirtos N et al. (2008) Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin © followed by elective T consolidation in advanced ovarian cancer: interim analysis of induction chemotherapy. J Clin Oncol 26 (suppl;abstr 5536)

    Google Scholar 

  65. Buyse M, Burzykowski T, Parmar M et al. (2003) Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. J Clin Oncol 21: 1682–1687

    Article  PubMed  Google Scholar 

  66. Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113–125

    Article  PubMed  CAS  Google Scholar 

  67. Trimbos JB, Parmar M, Vergote I et al. (2003) International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105–112

    Article  PubMed  Google Scholar 

  68. Elit L, Chambers A, Fyles A et al. (2004) Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer. 101: 1926–1935

    Article  PubMed  Google Scholar 

  69. Bell J, Brady MF, Young RC et al. (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102: 432–439

    Article  PubMed  CAS  Google Scholar 

  70. Ozols RF (1997) Future directions in the chemotherapy of ovarian cancer. Semin Oncol 24: S15

    PubMed  CAS  Google Scholar 

  71. Los G, Mutsaers PH, van der Vijgh WJ et al. (1989) Direct diffusion of cisdiamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380–3384

    PubMed  CAS  Google Scholar 

  72. Guastalla JP, Lhomme C, Kerbrat P et al. (1994) Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 5: 127–132

    PubMed  CAS  Google Scholar 

  73. Markman M, Reichman B, Hakes T et al. (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9: 1801–1805

    PubMed  CAS  Google Scholar 

  74. Goel R, McClay EF, Kirmani S et al. (1992) Pharmacokinetic study of intraperitoneal streptozotocin. Clin Invest Med 15: 420–426

    PubMed  CAS  Google Scholar 

  75. Muggia FM, Liu PY, Alberts DS et al. (1996) Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy—a randomized phase II study by theSouthwest Oncology Group. Gynecol Oncol 61: 395–402

    Article  PubMed  CAS  Google Scholar 

  76. Kirmani S, Braly PS, McClay EF et al. (1994) A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54: 338–344

    Article  PubMed  CAS  Google Scholar 

  77. Alberts DS, Liu PY, Hannigan EV, O’Toole R et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955

    Article  PubMed  CAS  Google Scholar 

  78. Markman M, Brady MF, Spirtos NM et al. (1998) Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 16: 2620–2624

    PubMed  CAS  Google Scholar 

  79. Gadducci A, Carnino F, Chiara S et al. (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 76: 157–162

    Article  PubMed  CAS  Google Scholar 

  80. Armstrong DK, Bundy B, Wenzel L et al. (2006) Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43

    Article  PubMed  CAS  Google Scholar 

  81. Hess LM, Benham-Hutchins M, Herzog TJ et al. (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17: 561–570

    Article  PubMed  CAS  Google Scholar 

  82. Piccart MJ, Floquet A, Scarfone G et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13(Suppl 2):196–203

    Article  PubMed  Google Scholar 

  83. Cure H, Battista RN, Guastalla J et al. (2004) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Journal of Clinical Oncology, Annual Meeting Proceedings (Post-Meeting Edition). 2214S [5006]. 2004. Ref Type: Abstract

    Google Scholar 

  84. Ray-Coquard I, Paraiso D, Guastalla JP et al. (2007) Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 97: 1200–1205

    Article  PubMed  CAS  Google Scholar 

  85. Sell A, Bertelsen K, Andersen JE et al. (1990) Randomized study of wholeabdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 37: 367–373

    Article  PubMed  CAS  Google Scholar 

  86. Berek JS, Bertelsen K, du Bois A et al. (2000) [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil 28: 576–583. Review. French

    PubMed  CAS  Google Scholar 

  87. Schwartz PE, Chambers JT, Kohorn EI et al. (1989) Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 63: 1074–1078

    Article  PubMed  CAS  Google Scholar 

  88. Berek JS, Welander C, Schink JC et al. (1991) A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40: 237–243

    Article  PubMed  CAS  Google Scholar 

  89. Pujade-Lauraine E, Guastalla JP, Colombo N et al. (1996). Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14: 343–350

    PubMed  CAS  Google Scholar 

  90. Alberts DS, Hannigan EV, Liu PY et al. (2006) Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol 100: 133–138. Epub 2005 Sep 8

    Article  PubMed  CAS  Google Scholar 

  91. Hall GD, Brown JM, Coleman RE et al. (2004) Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 91: 621–626

    Article  PubMed  CAS  Google Scholar 

  92. Berek JS, Taylor PT, Gordon A et al. (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004 22: 3507–3516

    Article  CAS  Google Scholar 

  93. Burger RA, Brady MF, Bookman MA et al. (2010) Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a gynecologic oncology group study. J Clin Oncol 28: part II 946s

    Google Scholar 

  94. Perren T, Swart AM, Psisterer J et al. (2010) ICON 7: A phase III randomised gynaecologic cancer intergroup followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal cancer or fallopian tube cancer. Ann Oncol 21: abstract

    Google Scholar 

  95. Cannistra SA, Matulonis UA, Penson RT et al. (2008) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25 (33):5180–5186. Erratum in: J Clin Oncol 26: 1773

    Google Scholar 

  96. Burger RA, Sill MW, Monk BJ et al. (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165–5171

    Article  PubMed  CAS  Google Scholar 

  97. Hirte H, Vergote IB, Jeffrey JR et al. (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102: 300–308

    Article  PubMed  CAS  Google Scholar 

  98. Dark GG, Bower M, Newlands ES et al. (1997) Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15: 620–624

    PubMed  CAS  Google Scholar 

  99. Wallace LM, Freeman T, Latham L et al. (2001) Organisational strategies for changing clinical practice: how trusts are meeting the challenges of clinical governance. Qual Health Care 10: 76–82

    Article  PubMed  CAS  Google Scholar 

  100. Rustin GJ, van der Burg ME, Griffin CL et al. (2010) MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376: 1155–1163

    Article  PubMed  Google Scholar 

  101. Markman M, Rothman R, Hakes T et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–393

    PubMed  CAS  Google Scholar 

  102. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol 8: 963–968

    Article  PubMed  CAS  Google Scholar 

  103. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10: 513–514

    PubMed  CAS  Google Scholar 

  104. Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36: 207–211

    Article  PubMed  CAS  Google Scholar 

  105. Bolis G, Scarfone G, Luchini L et al. (1994) Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin-or carboplatin-based regimen. Eur J Cancer 30A: 1764–1768

    Article  PubMed  CAS  Google Scholar 

  106. Markman M, Hakes T, Reichman B et al. (1992) Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this “new drug” in the management of platinum-refractory disease? Semin Oncol 19(6 Suppl 14): 25–27

    PubMed  CAS  Google Scholar 

  107. Ray-Coquard I, Weber B, Cretin J et al. (2009) Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 100: 601–607

    Article  PubMed  CAS  Google Scholar 

  108. Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71(4 Suppl): 1559–1564

    Article  PubMed  CAS  Google Scholar 

  109. Ozols RF (1999) Chemotherapy for ovarian cancer. Semin Oncol 26: 34–40. Review

    PubMed  CAS  Google Scholar 

  110. Pfisterer J, Vergote I, du Bois A, Eisenhauer E (2005) Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15Suppl 1: 36–41

    Article  PubMed  Google Scholar 

  111. Pujade-Lauraine E, Mahner S, Kaern J et al. (2009) A randomized phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer. CALYPSO study of the gynecologic cancer intergroup (GCIG). J Clin Oncol 18s(suppl;abstr LBA5509)

    Google Scholar 

  112. Poveda A, Vergote I, Tjulandin S et al. (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22: 39–48 (Epub 2010 Jul 19)

    Article  PubMed  CAS  Google Scholar 

  113. Markman M (1999) Concerns with “maintenance chemotherapy” for patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 73: 469–470

    Article  PubMed  CAS  Google Scholar 

  114. Koulouris CR, Penson RT (2009) Ovarian stromal and germ cell tumors. Semin Oncol 36: 126–136

    Article  PubMed  Google Scholar 

  115. Morice P (2006) Borderline tumours of the ovary and fertility. Eur J Cancer 42: 149–158

    Article  PubMed  CAS  Google Scholar 

  116. Timmers PJ, Zwinderman AH, Teodorovic I et al. (2009) Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer 19: 88–93

    Article  PubMed  CAS  Google Scholar 

  117. Kurman RJ, Shih I (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151–160

    PubMed  Google Scholar 

  118. Williams SD (1998) Ovarian germ cell tumors: an update. Semin Oncol 25: 407–413

    PubMed  CAS  Google Scholar 

  119. Ray-Coquard I, Cassier P, Treilleux I et al. (2004) Ovarian Rare tumors. Impact of a French-speaking website on medical practice and inclusions in a clinical trial. Results after 1 year. Eur J Cancer. 2004. Ref Type: Abstract

    Google Scholar 

  120. Colombo N, Parma G, Zanagnolo V, Insinga A (2007) Management of ovarian stromal cell tumors. J Clin Oncol 25: 2944–2951

    Article  PubMed  CAS  Google Scholar 

  121. Gershenson DM, Copeland LJ, Kavanagh JJ et al. (1987) Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 70: 765–769

    PubMed  CAS  Google Scholar 

  122. Homesley HD, Bundy BN, Hurteau JA, Roth LM (1999) Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study. Gynecologic Oncology 72: 131–137

    Article  PubMed  CAS  Google Scholar 

  123. Brown J, Shvartsman HS, Deavers MT et al. (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22: 3517–3523

    Article  PubMed  CAS  Google Scholar 

  124. Harter P, du B A, Schade-Brittinger C et al. (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16: 1801–1805

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Léon Bérard, 28, rue Laénnec, 69373, Lyon Cedex 08

    P. Heudel, I. Ray-Coquard, S. Racadot, H. Mignotte, T. Bachelot & J.-P. Guastalla

  2. Service de chirurgie, Centre Léon Bérard, 28, rue Laënnec, 69373, Lyon Cedex 08

    P. Méeus, I. Treilleux, I. Labidi, O. Trédan & F. Mithieux

  3. Service de chirurgie générale et endocrinienne, Hôpital Lyon-Sud, 165 Chemin Grand-Revoyet, 69495, Pierre-Bénite

    M. Peix

  4. Hôtel-Dieu de Paris, 1, Place du Parvis Notre-Dame, 75002, Paris

    E. Pujade Lauraine

  5. Service de gynécologie, Institut Gustave Roussy, 114, rue Édouard Vaillant, 94805, Villejuif

    P. Pautier

Authors
  1. P. Heudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Méeus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Treilleux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Labidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Trédan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Mithieux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Racadot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Peix
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Mignotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T. Bachelot
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. Pujade Lauraine
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Pautier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J.-P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Heudel, P. et al. (2011). Thérapeutiques du cancer de l’ovaire. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_33

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_33

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation